Clinicopathological features of appendiceal goblet cell adenocarcinoma in Japan: a multicenter retrospective study.
Additional operation
Appendix
Goblet cell adenocarcinoma
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
16
01
2022
accepted:
13
05
2022
pubmed:
2
8
2022
medline:
28
1
2023
entrez:
1
8
2022
Statut:
ppublish
Résumé
In the 5th edition of the World Health Organization classification, appendiceal goblet cell adenocarcinoma (GCA) is categorized separately from neuroendocrine tumors and other appendiceal adenocarcinomas. We clarified the clinicopathological characteristics of Japanese appendiceal GCA. We designed a retrospective multicenter cohort study and retrieved the data of patients with appendiceal neoplasms and histologically diagnosed appendiceal goblet cell carcinoid (GCC) treated from January 2000 to December 2017 in Japan. The available GCC slides were reviewed and diagnosed with a new grading system of GCA. A total of 922 patients from 43 institutions were enrolled; of these, 32 cases were patients with GCC (3.5%), and 20 cases were ultimately analyzed. The 5-year survival rate was 61.4% (95% confidence interval: 27.4-83.2), and the median survival time was 93.1 months. For peritoneal metastasis, regional lymph node metastasis was a significant factor (p = 0.04), and Grade 3 was a potential factor (p = 0.07). No peritoneal metastasis was observed in either T1/2 patients (n = 2) or Grade 1 patients (n = 4). We were unable to detect any significant factors associated with regional lymph node metastasis. For peritoneal metastasis, regional lymph node metastasis was a significant factor, and Grade 3 was a potential factor.
Identifiants
pubmed: 35913635
doi: 10.1007/s00595-022-02562-z
pii: 10.1007/s00595-022-02562-z
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174-181Informations de copyright
© 2022. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.
Références
Bosman FT, Carneiro F, Hruban RH, Theise ND. Tumours of the appendix. WHO Classification of Tumours of the Digestive system, WHO Classification of Tumours, 4th ed. vol.3, WHO; 2010. p. 120–9
Nagtegaal ID, Klimstra DS, Washington MK. Tumours of the appendix. WHO Classification of Tumours, Digestive system tumours: WORLD HEALTH ORGANIZATION; 5th ed. Vol.1, 2019. p. 136–55.
Yozu M, Johncilla ME, Srivastava A, Ryan DP, Cusack JC, Doyle L, et al. Histologic and outcome study supports reclassifying appendiceal goblet cell carcinoids as goblet cell adenocarcinomas, and grading and staging similarly to colonic adenocarcinomas. Am J Surg Pathol. 2018;42(7):898–910.
doi: 10.1097/PAS.0000000000001056
National Comprehensive Cancer Network. nccn clinical practice guidelines in oncology, colon cancer, version 1. 2020.
Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.
doi: 10.1007/s10147-019-01485-z
Moortele MV, Hertogh GD, Sagaert X, Cutsem EV. Appendiceal cancer: a review of the literature. Acta Gastroenterol Belg. 2020;83(3):441–8.
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. In: Digestive system tumours. Appendix. John Wiley & Sons; 2017. p. 70–2.
Dimmler A, Geddert H, Faller G. EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix. Pathol Res Pract. 2014;210(5):274–8.
doi: 10.1016/j.prp.2014.01.002
Wen KW, Grenert JP, Joseph NM, Shafizadeh N, Huang A, Hosseini M, et al. Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma. Hum Pathol. 2018;77:166–74.
doi: 10.1016/j.humpath.2018.03.026
Jesinghaus M, Konukiewitz B, Foersch S, Stenzinger A, Seiger K, Muckenhuber A, et al. Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. Mod Pathol. 2018;31(5):829–39.
doi: 10.1038/modpathol.2017.184
Johncilla M, Stachler M, Misdraji J, Lisovsky M, Yozu M, Lindeman N, et al. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Mod Pathol. 2018;31(6):989–96.
doi: 10.1038/s41379-018-0003-0
Stancu M, Wu TT, Wallace C, Houlihan PS, Hamilton SR, Rashid A. Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors. Mod Pathol. 2003;16(12):1189–98.
doi: 10.1097/01.MP.0000097362.10330.B1
Tsang ES, McConnell YJ, Schaeffer DF, Lee L, Yin Y, Zerhouni S, et al. Outcomes of surgical and chemotherapeutic treatments of goblet cell carcinoid tumors of the appendix. Ann Surg Oncol. 2018;25(8):2391–9.
doi: 10.1245/s10434-018-6560-0
Sluiter NR, van der Bilt JD, Croll DMR, Vriens MR, de Hingh IHJT, Hemmer P, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) versus surgery without hipec for goblet-cell carcinoids and mixed adenoneuroendocrine carcinomas: propensity score-matched analysis of centers in the Netherlands and Belgium. Clin Colorectal Cancer. 2020;19(3):e87-99.
doi: 10.1016/j.clcc.2020.01.002
Zambrano-Vera K, Sardi A, Munoz-Zuluaga C, Studeman K, Nieroda C, Sittig M, et al. Outcomes in peritoneal carcinomatosis from appendiceal goblet cell carcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Ann Surg Oncol. 2020;27(1):179–87.
doi: 10.1245/s10434-019-07932-5
Zakka K, Williamson S, Jiang R, Reid MD, Alese OB, Shaib WL, et al. Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix? Surg Oncol. 2020;36:120–9.
doi: 10.1016/j.suronc.2020.12.003
AlMasri S, Nassour I, Kowalsky S, Hrebinko K, Singhi AD, Lee KK, et al. The role of adjuvant chemotherapy in non-metastatic goblet cell carcinoid of the appendix: an 11-year experience from the national cancer database. Ann Surg Oncol. 2021;28(7):3873–81.
doi: 10.1245/s10434-020-09389-3
Tang LH, Shia J, Soslow RA, Dhall D, Wong WD, O’Reilly E, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008;32(10):1429–43.
doi: 10.1097/PAS.0b013e31817f1816
Taggart MW, Abraham SC, Overman MJ, Mansfield PF, Rashid A. Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch Pathol Lab Med. 2015;139(6):782–90.
doi: 10.5858/arpa.2013-0047-OA
Lee LH, McConnell YJ, Tsang E, Zerhouni S, Speers C, Kennecke H, et al. Simplified 2-tier histologic grading system accurately predicts outcomes in goblet cell carcinoid of the appendix. Hum Pathol. 2015;46(12):1881–9.
doi: 10.1016/j.humpath.2015.08.005